TAGS: Natural/ Organic
Creo, a cannabinoid ingredient company, announces its official launch in collaboration with Genomatica. Creo in partnership with Genomatica has been developing fermentation-based cannabinoid production technologies since 2016. Creo was co-founded by science entrepreneur and CEO, Roy Lipski, and leading professor of bioengineering, Dr. Ramon Gonzalez.
Creo: High-quality Cannabinoid Ingredients
Creo has the technology to deliver a reliable, high-quality and consistent supply of rare and novel cannabinoid ingredients at commercial scale. With its launch, Creo’s customers will gain access to new ingredients that support their development of innovative products.
“
As early as 2015, we recognized the untapped potential of biotechnology to make cannabinoids better. Now working alongside our technology partner Genomatica, we have built a strong IP position, developed our core technology, and are ready to move to commercial scale,” said Roy Lipski, co-founder, science entrepreneur and CEO, Creo.
First Product: Mother of All Cannabinoids
Creo’s first product, CBG, is sometimes called the “mother cannabinoid” or “skin cannabinoid,” and is the parent molecule from which other cannabinoids are made. Because CBG is mostly converted into other cannabinoids, such as THC and CBD, very little of it remains intact in the plant.
“
We are fully committed to Creo in the field of cannabinoids and have strong confidence in their team and the market opportunity,” said Christophe Schilling, co-founder and CEO, Genomatica. “
We believe in positive disruptors and are proud to stand by Creo at its launch, and to bring the power of our proven technology innovation engine.”
Creo’s brand is built on three core pillars: sustainable innovation, access to abundance and being a trusted partner to customers. Creo’s promise of greater sustainability is why it makes its cannabinoid ingredients using one of the world’s oldest natural processes – fermentation.
Source: Creo